Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 9/2009

Open Access 01-09-2009 | Original Article

Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study

Authors: S. Pouwels, T. P. van Staa, A. C. G. Egberts, H. G. M. Leufkens, C. Cooper, F. de Vries

Published in: Osteoporosis International | Issue 9/2009

Login to get access

Abstract

Summary

This case–control study showed that current use of conventional antipsychotics, but not atypical antipsychotics, seems to be associated with an increased risk of a hip/femur fracture, possibly related to the pharmacological properties of conventional antipsychotics. Furthermore, no evidence for a dose effect was found.

Introduction

The aim of this study was to assess the risk of hip/femur fracture associated with antipsychotic use, with particular reference to any difference in risk with conventional versus atypical antipsychotics, dose, and pharmacological properties.

Methods

A case–control study was conducted using data from the PHARMO Record Linkage System among individuals aged 18 years and older between 1991 and 2002. Cases had a record of a hip or femur fracture, while controls had no evidence of ever having sustained any fracture.

Results

Most cases were elderly (77.6% aged ≥70 years). We found an increased risk for hip/femur fracture associated with the use of antipsychotic drugs. The risk for current users (ORadj 1.68 [1.43, 1.99]) was significantly greater than with past use (ORadj 1.33 [1.14, 1.56]; p = 0.036). Current use of conventional antipsychotics (ORadj 1.76 [1.48, 2.08]) but not atypical antipsychotics (ORadj 0.83 [0.42, 1.65]) was associated with an increased risk. We did not find evidence for a dose effect.

Conclusion

The use of conventional, but not atypical antipsychotics, seems to be associated with an increased risk of hip/femur fracture, possibly related to the pharmacological properties of conventional antipsychotics. However, the numbers of atypical antipsychotic users were small, and therefore this observation needs further attention in other study populations.
Literature
1.
Rang HP et al (1999) Pharmacology, 4th edn. Churchill Livingstone, Edinburgh
2.
Jeste DV, Dolder CR (2004) Treatment of non-schizophrenic disorders: focus on atypical antipsychotics. J Psychiatr Res 38(1):73–103PubMedCrossRef
3.
Neutel CI, Perry S, Maxwell C (2002) Medication use and risk of falls. Pharmacoepidemiol Drug Saf 11(2):97–104PubMedCrossRef
4.
Miyamoto S et al (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10(1):79–104PubMedCrossRef
5.
Melkersson KI, Hulting AL, Rane AJ (2001) Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51(4):317–324PubMedCrossRef
6.
Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64(20):2291–314PubMedCrossRef
7.
Van de Kar LD et al (2001) 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 21(10):3572–3579PubMed
8.
Misra M, Papakostas GI, Klibanski A (2004) Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65(12):1607–1618 quiz 1590, 1760–1761PubMedCrossRef
9.
Meaney AM et al (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184:503–508PubMedCrossRef
10.
O’Keane V, Meaney AM (2005) Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia. J Clin Psychopharmacol 25(1):26–31PubMedCrossRef
11.
Diem SJ et al (2007) Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167(12):1240–1245PubMedCrossRef
12.
Richards JB et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167(2):188–194PubMedCrossRef
13.
Howard L, Kirkwood G, Leese M (2007) Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 190:129–134PubMedCrossRef
14.
Cumming RG, Klineberg RJ (1993) Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 158(6):414–417PubMed
15.
Liperoti R et al (2007) Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case–control study. J Clin Psychiatry 68(6):929–934PubMedCrossRef
16.
Ray WA et al (1987) Psychotropic drug use and the risk of hip fracture. N Engl J Med 316(7):363–369PubMed
17.
Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17(6):807–816PubMedCrossRef
18.
Hugenholtz GW et al (2005) Risk of hip/femur fractures in patients using antipsychotics. Bone 37(6):864–870PubMedCrossRef
19.
Sernbo I, Hansson A, Johnell O (1987) Drug consumption in patients with hip fractures compared with controls. Compr Gerontol [A] 1(3):93–96
20.
Buurma H et al (2008) Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 33(1):17–23PubMed
21.
Herings RM et al (1996) Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 49(1):115–119PubMedCrossRef
22.
de Vries F et al (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study. J Intern Med 261(2):170–177PubMed
23.
de Vries F et al (2007) Use of beta-2 agonists and risk of hip/femur fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf 16(6):612–619PubMedCrossRef
24.
de Vries F et al (2007) Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 80(2):69–75PubMedCrossRef
25.
WHO (2005) WHO Collaborating Centre for drug statistics methodology. The ATC/DDD system. World Health Organisation
26.
Becker D et al (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 64(7):761–766PubMedCrossRef
27.
Koda-Kimble MA, Young LY, Kradjan WA (2003) Applied therapeutics: the clinical use of drugs, 7th edn. . Lippincott, Williams & Wilkins, New York
28.
Speight TM, Holford NHG (1997) Avery’s drug treatment: A guide to the properties, choice, therapeutic use and economic value of drugs in disease management, 4th edn. Adis Press, Auckland
29.
AMAM (1996) American Medical Association. Division of Drugs and Toxicology. Drug Evaluations Annual, Chicago
30.
Hummer M et al (2005) Osteoporosis in patients with schizophrenia. Am J Psychiatry 162(1):162–167PubMedCrossRef
31.
Petty RG (1999) Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 35(Suppl):S67–S73PubMedCrossRef
32.
Warrel DA, Cox TM, Firth JD (2005) Oxford textbook of medicine, vol. 3. 4th edn. Oxford University Press, Oxford
33.
Grisso JA, Capezuti E, Schwartz A (1996) Falls as risk factors for fractures. In: Marcus D, Kelsey J, Feldman D (eds) Osteoporosis. Academic, San Diego, pp 599–611
34.
Cummings SR et al (1995) Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. N Engl J Med 332(12):767–773PubMedCrossRef
35.
Owens DC (1999) A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge University Press, Cambridge
36.
37.
Cauley JA et al (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16(12):1525–1537PubMedCrossRef
38.
Alanen HM et al (2006) Use of antipsychotic medications among elderly residents in long-term institutional care: a three-year follow-up. Int J Geriatr Psychiatry 21(3):288–295PubMedCrossRef
39.
Jeste DV et al (2008) ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33(5):957–970PubMedCrossRef
40.
Melton LJ III et al (1994) Fracture risk in patients with Alzheimer’s disease. J Am Geriatr Soc 42:614–619PubMed
41.
van Staa TP et al (2002) Utility of medical and drug history in fracture risk prediction among men and women. Bone 31:508–514PubMedCrossRef
42.
Whooley MA et al (1999) Depression, falls, and risk of fracture in older women. Arch Intern Med 159(5):484–490PubMedCrossRef
43.
Bolton JM et al (2008) Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 28(4):384–391PubMedCrossRef
Metadata
Title
Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study
Authors
S. Pouwels
T. P. van Staa
A. C. G. Egberts
H. G. M. Leufkens
C. Cooper
F. de Vries
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 9/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0826-5

Other articles of this Issue 9/2009

Osteoporosis International 9/2009 Go to the issue

Letter to the Editor

Comment on Kanis et al.: “European guidance for the diagnosis and management of osteoporosis in postmenopausal women”

Original Article

The association between socioeconomic status and osteoporotic fracture in population-based adults: a systematic review

Original Article

Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study

Original Article

Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures

Short Communication

Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis

Original Article

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression